Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.83+0.04 (+2.23%)
Close on Nov 17, 2026Market cap $108.68MP/E –Yield –
Foghorn Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Foghorn Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $36.74M, up 52.0% year over year. For fiscal 2025 it was $30.91M, up 36.8% from the year before. The highest annual figure on record is $34.16M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.91M | +36.8% |
| FY2024 | Dec 31, 2024 | $22.60M | -33.8% |
| FY2023 | Dec 31, 2023 | $34.16M | +77.6% |
| FY2022 | Dec 31, 2022 | $19.23M | +1357.8% |
| FY2021 | Dec 31, 2021 | $1.32M | +206.7% |
| FY2020 | Dec 31, 2020 | $430.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.07M | +112.7% |
| Q1 FY2026 | Mar 31, 2026 | $3.27M | -45.1% |
| Q4 FY2025 | Dec 31, 2025 | $9.25M | +223.8% |
| Q3 FY2025 | Sep 30, 2025 | $8.15M | +4.4% |
| Q2 FY2025 | Jun 30, 2025 | $7.56M | +9.7% |
| Q1 FY2025 | Mar 31, 2025 | $5.95M | +17.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.86M | -50.5% |
| Q3 FY2024 | Sep 30, 2024 | $7.81M | -55.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.89M | +23.0% |
| Q1 FY2024 | Mar 31, 2024 | $5.05M | -4.9% |
| Q4 FY2023 | Dec 31, 2023 | $5.77M | +37.9% |
| Q3 FY2023 | Sep 30, 2023 | $17.48M | +163.5% |
| Q2 FY2023 | Jun 30, 2023 | $5.60M | +24.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.31M | +35.4% |
| Q4 FY2022 | Dec 31, 2022 | $4.18M | +486.8% |
| Q3 FY2022 | Sep 30, 2022 | $6.63M | +16080.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.49M | +1509.3% |
| Q1 FY2022 | Mar 31, 2022 | $3.92M | +1270.6% |
| Q4 FY2021 | Dec 31, 2021 | $713.00K | +184.1% |
| Q3 FY2021 | Sep 30, 2021 | $41.00K | -77.1% |
| Q2 FY2021 | Jun 30, 2021 | $279.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $286.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $251.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $179.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
See a number that looks wrong?